UCB S A ORDINARY SHARES BELGIUM (OTCMKTS:UCBJF) reported an increase of 0.44% in shorted shares. In February was published UCBJF’s total 481,500 shorted shares by FINRA. The 479,400 previous shares are up with 0.44%. 2408 days will cost UCBJF with 200 average volume to recover its previous position.
At traded at $88.67 lastly.Since February 24, 2018 it’s 0.00% down thus . UCBJF the S&P500 by 0.00%.
UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system.The firm is worth $16.95 billion. The Company’s core products include Cimzia for ankylosing spondylitis, axial spondyloarthritis, Crohn??s disease, psoriatic arthritis, and rheumatoid arthritis; Keppra, Vimpat, and Briviact for epilepsy; and Neupro for Parkinson??s disease and restless legs syndrome.16.42 is the P/E ratio. The firm also offers Zyrtec and Xyzal for allergy; Venlafaxine ER for depressive and anxiety disorders; Nootropil for cognitive disorders; and Xyrem for narcolepsy.
More recent UCB SA (OTCMKTS:UCBJF) news were released by Seekingalpha.com, Seekingalpha.com and Seekingalpha.com. The first one has “UCB S.A. ADR 2018 Q2 – Results – Earnings Call Slides – Seeking Alpha” as a title and was released on July 26, 2018. The next is “EMA accepts UCB’s marketing application for osteoporosis med romosozumab – Seeking Alpha” on January 08, 2018. And last was released on May 16, 2018, called “UCB’s Cimzia successful in late-stage study in subtype of ankylosing spondylitis – Seeking Alpha”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.